Overview

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Status:
Active, not recruiting

Trial end date:
2026-09-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

Phase:

Phase 3

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborators:

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Treatments:

Leuprolide